Avery Therapeutics, Inc.
Monday, June 03, 2024
Platform for Therapeutics
Company Presentation Theater 4
Avery Therapeutics is developing first-in-class immunomodulatory therapeutics to redirect the immune system to address diseases of aging, inflammation, and fibrosis. Avery's lead program is under development for heart failure, one of the leading causes of death in the world.
Company Website:
https://averythera.com
Lead Product in Development:
Novel immunomodulatory platform
Company HQ City
Tucson
Company HQ State
AZ
Company HQ Country
United States
CEO/Top Company Official
Jordan Lancaster
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
.jpg)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())